Neurocrine Biosciences (NBIX)
Add to Watchlists Create an Alert
12.32
+0.31 +2.58%
NASDAQ
May 23, 11:35AM
BATS Real time
Currency in USD
Neurocrine Biosciences Return on Equity:
-4.22% for March 31, 2013Neurocrine Biosciences Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | -4.22% |
| Dec. 31, 2012 | 3.89% |
| Sept. 30, 2012 | -2.85% |
| June 30, 2012 | 36.26% |
| March 31, 2012 | 54.48% |
| Dec. 31, 2011 | 101.1% |
| Sept. 30, 2011 | 136.1% |
| June 30, 2011 | 55.07% |
| March 31, 2011 | 20.14% |
| Dec. 31, 2010 | -57.67% |
| Sept. 30, 2010 | -180.8% |
| June 30, 2010 | -359.9% |
| March 31, 2010 | -415.0% |
| Dec. 31, 2009 | -373.8% |
| Sept. 30, 2009 | -281.3% |
| June 30, 2009 | -197.1% |
| March 31, 2009 | -146.3% |
| Dec. 31, 2008 | -111.4% |
| Sept. 30, 2008 | -154.9% |
| June 30, 2008 | -121.6% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
NBIX Return on Equity Benchmarks
| Companies | |
|---|---|
| Abbott Laboratories | 23.27% |
| Insmed | -32.34% |
| Celldex Therapeutics | -53.87% |
NBIX Return on Equity Rankings
| Overall |
56th percentile 3450 of 8006 |
| Sector |
63rd percentile 248 of 686 in Healthcare |
| Industry |
65th percentile 19 of 55 in Drug Manufacturers - Major |
NBIX Return on Equity Range, Past 5 Years
| Minimum | -415.0% | Mar 2010 |
| Maximum | 136.1% | Sep 2011 |
| Average | -99.99% |
